CYP 2.33% 21.0¢ cynata therapeutics limited

Ann: Efficacy for CYP MSC Technology in Preclinical Asthma Study-CYP.AX, page-32

  1. 569 Posts.
    lightbulb Created with Sketch. 130
    Agreed. This technology will fundamentally change the oncology field and probably put a good dent in drug company cytotoxic revenue streams. Perhaps even more impetus to buy Cynata out =)
    Last edited by Tifosi: 17/10/16
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.